+44 7723 059341
Scientific and strategic support for the development of robust, productive and stable mammalian production cell lines, aligned with CMC development needs – from host and vector choices through clone selection and handover to upstream process development.
Where it goes wrong: clone instability, weak selection stringency, a host chosen before the CMC path was clear. Z2 builds the CLD plan around the molecule and its route to the clinic.
What we do
- Host-cell, selection-system and vector/expression strategy
- Expression architecture and early programme design
- Pool and clone screening strategy and clone selection
- Productivity, product-quality and stability considerations
- Troubleshooting, data review and risk assessment
- Decision-making through handover to upstream process development
Throughout, with appropriate consideration of cell substrate, process and future CMC requirements.
Complex formats need a plan for the molecule
Engineered formats now make up one-third of approved antibody medicines, bispecific trials are up 256% since 2019, and the first trispecific approvals are expected around 2028.1,2,3 Standard IgG mAbs still account for two-thirds of approvals and 69% of biologics revenue (2024), so most platforms are built for them.4 Reusing a standard mAb platform for a complex format is where rushed timelines break.5
| Format | Main development problem |
|---|---|
| Standard IgG mAb (baseline) | Mature platform process; fed-batch titres above 10 g/L achievable6 |
| Bispecific (IgG-like) | Chain mispairing, homodimers, heavy-chain clipping and aggregation5 |
| Trispecific | Three binding arms to assemble; higher manufacturing cost; none approved yet3 |
| Fragments (Fab, scFv, VHH) | Inclusion bodies and endotoxin in E. coli; scFv aggregation; short half-life without Fc7 |
| Fusion proteins | Lower expression and greater sensitivity to culture conditions than a standard mAb5 |
The race to file can leave the clone unproven
Speed-first CDMO packages can cut CMC work before first-in-human from around 15 months for a clonal cell line to 3 months with a non-clonal pool – an 80% cut.8 What gets compressed carries risk:
Clonality
FDA expects high assurance of single-cell origin, e.g. two rounds of limiting dilution below 0.5 cells per well9
Pools
Not recommended for Phase 1; moving to a clone later needs a full comparability study10
8–63%
of CHO lines prove unstable – short studies miss late productivity drift11
Where rushed timelines break
Clone-selection and stability criteria are rarely agreed before the CDMO starts, or checked before the clonality package reaches the regulator.
Where Z2 helps
Complexity is rising. Z2 builds a CLD plan for the format: chain ratios, host choice, stability and clonality criteria – agreed up front and reviewed independently.
Sources
- Strohl WR, Antibody Therapeutics. Structure and function of therapeutic antibodies approved by the US FDA in 2025, 2026.
- Prime Therapeutics. Oncology Insights, June 2025 (bispecific trials since 2019).
- Trispecific antibodies in cancer therapy, PubMed 41855774, 2026; Labiotech, The rise of trispecific antibodies, May 2026.
- Grand View Research. Global biologics market size and outlook, 2024–2030 (Horizon Databook), 2026.
- Antibody Therapeutics. Challenges and solutions for upstream processing of complex biologics, 2026 (doi 10.1093/abt/tbag008).
- Engineering in Life Sciences. Increased MSX level improves productivity in GS CHO cell lines (PMC7447880).
- Bioengineering of antibody fragments: challenges and opportunities, Bioengineering 2023 (PMC9952581).
- Further accelerating biologics development from DNA to IND. WuXi Biologics perspective (PMC10873266).
- US Patent 11,851,662. Summarises FDA clonality expectations (Kennett 2014; Novak 2017; Welch 2017).
- BioProcess International. Production cell line development: myths, risks and best practices.
- US Patent 10,913,984. Predicting genetically stable recombinant protein production in early cell line development (review of published DHFR/GS CHO stability data).
